Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Esketamine (Spravato°) in depression after failure of several antidepressants or with a high risk of suicide?

 Marketing Authorisations  The publication in 2023 of results from the trial comparing esketamine to quetiapine provides an opportunity to review the evaluation data on esketamine in the situations for which it is authorised. Since our 2022 analysis, what more is known about the efficacy of esketamine in comparison to that of other treatments? What more is known about its adverse effects?
Full article available for download by subscribers

 ©Prescrire 1 April 2025

Source: "Esketamine (Spravato°) in depression after failure of several antidepressants or with a high risk of suicide" Prescrire Int 2025; 34 (269): 89-91. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:

"Esketamine (Spravato°)
and “treatment-resistant”
depression. Huge risks
for uncertain efficacy"
Prescrire Int 2021;
30 (222): 5-9.
Subscribers only
 

"Esketamine (Spravato°) 
in depression with 
a high risk of suicide"
Prescrire Int 2022;
31 (238): 150-151.
Subscribers only

 

Read more:

This month's contents

All the subjects in
Prescrire's spotlight